Drug Pricing Myths and Realities

Turing Pharmaceuticals CEO Martin Shkreli and his notorious $750 pill have brought new media attention and public outcry to the already contentious issue of drug pricing. But Beth Roberts, partner in the health group at Hogan Lovells, argues that while profiteering stories get the bulk of the attention, the issue of drug pricing is much more complex. Roberts shares her views on some of the most common misperceptions related to the crucial issue of drug pricing.

Click here to watch the video.

Download PDF Back To Listing
Loading data